CNS1022: A Phase II Randomized Trial of Lenalidomide (NSC#703813, IND#70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gliomas


Brain Tumor : Recurrent, refractory or progressive brain tumors


This is a phase II randomized study to compare two doses of the study drug, lenalidomide, for the treatment of children with recurrent, refractory or progressive juvenile pilocytic astrocytoma (JPA) and optic pathway gliomas. Lenalidomide will be given by mouth for 3 weeks, followed by 1 week of rest. Treatment can continue for 26 cycles or 2 years, unless there is disease progression or unacceptable side effects. Correlative pharmacokinetic studies will be done.




Ibrahim Qaddoumi, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Phone: 901-595-2544 or 901-595-4599
FAX: 901-595-5353


Tabatha E. Doyle, RN
Coordinator, Brain Tumor Program
Phone: 901-595-2544

For the current eligibility status of this clinical study, patient’s family, relatives and/or referring physicians may contact St. Jude Children’s Research Hospital at (901) 595-4599 or (901) 595-2544.

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.